Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
We have seen a notable increase in the application of PD-1/PD-L1 inhibitors for the treatment of several solid and hematogenous malignancies including metastatic melanoma, non-small-cell lung cancer and lymphoma to name a few. The need for biomarkers for identification of a suitable patient populati...
Gespeichert in:
| Veröffentlicht in: | Biomarker research 2017-03, Vol.5 (1), p.12, Article 12 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 12 |
| container_title | Biomarker research |
| container_volume | 5 |
| creator | Diggs, Laurence P Hsueh, Eddy C |
| description | We have seen a notable increase in the application of PD-1/PD-L1 inhibitors for the treatment of several solid and hematogenous malignancies including metastatic melanoma, non-small-cell lung cancer and lymphoma to name a few. The need for biomarkers for identification of a suitable patient population for this type of therapy is now pressing. While specific biomarker assays have been developed for these checkpoint inhibitors based on their respective epitopes, the available studies suggested the clinical utility of these biomarker assays is for response stratification and not patient selection. Further improvement in assay development is needed to utilize this type of assay in identification of ideal patient population for this therapy. |
| doi_str_mv | 10.1186/s40364-017-0093-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5353958</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1883084474</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-5dff52b3fe32702ecbcf197725002bd710d5b732cc4a910f4b50bfd9e25576153</originalsourceid><addsrcrecordid>eNpdkU9r3DAQxUVpaEKyH6CXYuilFycz-rOSL4WQpE1hITlkDz0JW5ayCra1kezAfvvI7Dak0WUE895jHj9CviKcI6rlReLAlrwElCVAxUr1iZxQEFBKKfHzu_8xWaT0BPkpxRGrL-SYKsZwifSE_F2PvvPjrgiuuL8uV1j4vp-GsPFpDGZj-zzjrqhTqnepcCEW22hbb0Y_PM4GvDi4ho1v_Jj30aZtGJI9I0eu7pJdHOYpWf-6ebi6LVd3v_9cXa5Kwys2lqJ1TtCGOcuoBGpNYxxWUlIBQJtWIrSikYwaw-sKwfFGQOPaylIh5BIFOyU_97nbqelta-wwxrrT2-j7Ou50qL3-fzP4jX4ML1owwSqhcsCPQ0AMz5NNo86lje26erBhShqVAi4Zcpql3z9In8IUh1xvVjFQnEueVbhXmRhSita9HYOgZ3Z6z05ndnpmp-cjvr1v8eb4R4q9AqUxlCw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1883084474</pqid></control><display><type>article</type><title>Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response</title><source>DOAJ Directory of Open Access Journals</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Diggs, Laurence P ; Hsueh, Eddy C</creator><creatorcontrib>Diggs, Laurence P ; Hsueh, Eddy C</creatorcontrib><description>We have seen a notable increase in the application of PD-1/PD-L1 inhibitors for the treatment of several solid and hematogenous malignancies including metastatic melanoma, non-small-cell lung cancer and lymphoma to name a few. The need for biomarkers for identification of a suitable patient population for this type of therapy is now pressing. While specific biomarker assays have been developed for these checkpoint inhibitors based on their respective epitopes, the available studies suggested the clinical utility of these biomarker assays is for response stratification and not patient selection. Further improvement in assay development is needed to utilize this type of assay in identification of ideal patient population for this therapy.</description><identifier>ISSN: 2050-7771</identifier><identifier>EISSN: 2050-7771</identifier><identifier>DOI: 10.1186/s40364-017-0093-8</identifier><identifier>PMID: 28331612</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject>Bioassays ; Biomarkers ; Clinical trials ; Epitopes ; Gene expression ; Immune checkpoint ; Immunoglobulins ; Immunohistochemistry ; Kinases ; Ligands ; Lung cancer ; Lymphoma ; Medical prognosis ; Melanoma ; Metastases ; Patients ; PD-1 protein ; PD-L1 protein ; Review ; Studies ; Tumors</subject><ispartof>Biomarker research, 2017-03, Vol.5 (1), p.12, Article 12</ispartof><rights>Copyright BioMed Central 2017</rights><rights>The Author(s). 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-5dff52b3fe32702ecbcf197725002bd710d5b732cc4a910f4b50bfd9e25576153</citedby><cites>FETCH-LOGICAL-c493t-5dff52b3fe32702ecbcf197725002bd710d5b732cc4a910f4b50bfd9e25576153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353958/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353958/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28331612$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Diggs, Laurence P</creatorcontrib><creatorcontrib>Hsueh, Eddy C</creatorcontrib><title>Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response</title><title>Biomarker research</title><addtitle>Biomark Res</addtitle><description>We have seen a notable increase in the application of PD-1/PD-L1 inhibitors for the treatment of several solid and hematogenous malignancies including metastatic melanoma, non-small-cell lung cancer and lymphoma to name a few. The need for biomarkers for identification of a suitable patient population for this type of therapy is now pressing. While specific biomarker assays have been developed for these checkpoint inhibitors based on their respective epitopes, the available studies suggested the clinical utility of these biomarker assays is for response stratification and not patient selection. Further improvement in assay development is needed to utilize this type of assay in identification of ideal patient population for this therapy.</description><subject>Bioassays</subject><subject>Biomarkers</subject><subject>Clinical trials</subject><subject>Epitopes</subject><subject>Gene expression</subject><subject>Immune checkpoint</subject><subject>Immunoglobulins</subject><subject>Immunohistochemistry</subject><subject>Kinases</subject><subject>Ligands</subject><subject>Lung cancer</subject><subject>Lymphoma</subject><subject>Medical prognosis</subject><subject>Melanoma</subject><subject>Metastases</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>PD-L1 protein</subject><subject>Review</subject><subject>Studies</subject><subject>Tumors</subject><issn>2050-7771</issn><issn>2050-7771</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkU9r3DAQxUVpaEKyH6CXYuilFycz-rOSL4WQpE1hITlkDz0JW5ayCra1kezAfvvI7Dak0WUE895jHj9CviKcI6rlReLAlrwElCVAxUr1iZxQEFBKKfHzu_8xWaT0BPkpxRGrL-SYKsZwifSE_F2PvvPjrgiuuL8uV1j4vp-GsPFpDGZj-zzjrqhTqnepcCEW22hbb0Y_PM4GvDi4ho1v_Jj30aZtGJI9I0eu7pJdHOYpWf-6ebi6LVd3v_9cXa5Kwys2lqJ1TtCGOcuoBGpNYxxWUlIBQJtWIrSikYwaw-sKwfFGQOPaylIh5BIFOyU_97nbqelta-wwxrrT2-j7Ou50qL3-fzP4jX4ML1owwSqhcsCPQ0AMz5NNo86lje26erBhShqVAi4Zcpql3z9In8IUh1xvVjFQnEueVbhXmRhSita9HYOgZ3Z6z05ndnpmp-cjvr1v8eb4R4q9AqUxlCw</recordid><startdate>20170315</startdate><enddate>20170315</enddate><creator>Diggs, Laurence P</creator><creator>Hsueh, Eddy C</creator><general>BioMed Central</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170315</creationdate><title>Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response</title><author>Diggs, Laurence P ; Hsueh, Eddy C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-5dff52b3fe32702ecbcf197725002bd710d5b732cc4a910f4b50bfd9e25576153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Bioassays</topic><topic>Biomarkers</topic><topic>Clinical trials</topic><topic>Epitopes</topic><topic>Gene expression</topic><topic>Immune checkpoint</topic><topic>Immunoglobulins</topic><topic>Immunohistochemistry</topic><topic>Kinases</topic><topic>Ligands</topic><topic>Lung cancer</topic><topic>Lymphoma</topic><topic>Medical prognosis</topic><topic>Melanoma</topic><topic>Metastases</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>PD-L1 protein</topic><topic>Review</topic><topic>Studies</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Diggs, Laurence P</creatorcontrib><creatorcontrib>Hsueh, Eddy C</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biomarker research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Diggs, Laurence P</au><au>Hsueh, Eddy C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response</atitle><jtitle>Biomarker research</jtitle><addtitle>Biomark Res</addtitle><date>2017-03-15</date><risdate>2017</risdate><volume>5</volume><issue>1</issue><spage>12</spage><pages>12-</pages><artnum>12</artnum><issn>2050-7771</issn><eissn>2050-7771</eissn><abstract>We have seen a notable increase in the application of PD-1/PD-L1 inhibitors for the treatment of several solid and hematogenous malignancies including metastatic melanoma, non-small-cell lung cancer and lymphoma to name a few. The need for biomarkers for identification of a suitable patient population for this type of therapy is now pressing. While specific biomarker assays have been developed for these checkpoint inhibitors based on their respective epitopes, the available studies suggested the clinical utility of these biomarker assays is for response stratification and not patient selection. Further improvement in assay development is needed to utilize this type of assay in identification of ideal patient population for this therapy.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>28331612</pmid><doi>10.1186/s40364-017-0093-8</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2050-7771 |
| ispartof | Biomarker research, 2017-03, Vol.5 (1), p.12, Article 12 |
| issn | 2050-7771 2050-7771 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5353958 |
| source | DOAJ Directory of Open Access Journals; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access; Springer Nature OA Free Journals |
| subjects | Bioassays Biomarkers Clinical trials Epitopes Gene expression Immune checkpoint Immunoglobulins Immunohistochemistry Kinases Ligands Lung cancer Lymphoma Medical prognosis Melanoma Metastases Patients PD-1 protein PD-L1 protein Review Studies Tumors |
| title | Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T21%3A34%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utility%20of%20PD-L1%20immunohistochemistry%20assays%20for%20predicting%20PD-1/PD-L1%20inhibitor%20response&rft.jtitle=Biomarker%20research&rft.au=Diggs,%20Laurence%20P&rft.date=2017-03-15&rft.volume=5&rft.issue=1&rft.spage=12&rft.pages=12-&rft.artnum=12&rft.issn=2050-7771&rft.eissn=2050-7771&rft_id=info:doi/10.1186/s40364-017-0093-8&rft_dat=%3Cproquest_pubme%3E1883084474%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1883084474&rft_id=info:pmid/28331612&rfr_iscdi=true |